Physician profile
Bridget Ory
NPI 1639226434
$859.80
in general payments reported to CMS, 2019-2025
12 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.04 · 2020: $139 · 2021: $125 · 2022: $122 · 2023: $115 · 2024: $146 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $191.26 | 2019-2023 | Nuzyra |
| Shionogi INC | $125.00 | 2021 | |
| Astellas Pharma US INC | $122.81 | 2024 | Cresemba |
| Gilead Sciences, INC. | $122.26 | 2022 | |
| Abbvie INC. | $117.66 | 2025 | |
| Smith+Nephew, INC. | $62.54 | 2019-2025 | Renasys Touch, Pico 14 |
| Allergan, INC. | $26.24 | 2019-2020 | |
| Solventum Corporation | $22.73 | 2024 | Activ.A.C., V.A.C. Granufoam |
| Kestra Medical Technology Services, INC. | $21.72 | 2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $17.67 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.54 | 2020 | |
| Melinta Therapeutics, LLC | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Ory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.